[AAVL] Avalanche Biotechnologies, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 111.74 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.14 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AAVL

Refresh chart

Description: Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform. Its lead product candidate includes AVA-101, which is in a Phase I/IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, an anti-vascular endothelial growth factor gene therapy product candidate for the prevention of wet AMD; and AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding26.99 M EPS-1.8 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 50.37% Sales Growth - Q/Q0% P/E-2.4
P/E To EPS Growth P/S156.51 P/BV0.42 Price/Cash Per Share
Price/Free Cash Flow-16.95 ROA-11.36% ROE-11.89% ROI
Current Ratio38.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin-4343.22% Net Profit Margin-4463.09% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.97 M Cash From Investing Activities-88.78 M Cash From Operating Activities-7.74 M Gross Profit
Net Profit-9.51 M Operating Profit-9.56 M Total Assets292.69 M Total Current Assets291.13 M
Total Current Liabilities7.63 M Total Debt Total Liabilities13.01 M Total Revenue200 K
Technical Data
High 52 week41.4 Low 52 week4.03 Last close4.14 Last change-4.17%
RSI17.06 Average true range0.35 Beta1.18 Volume
Simple moving average 20 days-22.33% Simple moving average 50 days-21.29% Simple moving average 200 days-47.76%
Performance Data
Performance Week-17.03% Performance Month-18.66% Performance Quart-9.41% Performance Half-55.77%
Performance Year-87.78% Performance Year-to-date-56.51% Volatility daily5.14% Volatility weekly11.48%
Volatility monthly23.54% Volatility yearly81.53% Relative Volume0% Average Volume339.18 K
New High New Low

News

2016-11-09 09:09:03 | Adverum Biotechnologies to Present at Upcoming Investor Conferences

2016-11-08 16:19:15 | Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results

2016-10-14 07:20:01 | Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO

2016-10-14 07:20:01 | Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program

2016-09-16 07:28:05 | Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting

2016-08-09 16:30:07 | Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results

2016-08-09 07:20:16 | Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye

2016-07-07 16:31:08 | Adverum Biotechnologies Provides wet AMD Program Update

2016-06-13 08:49:04 | Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer

2016-05-12 11:17:09 | AVALANCHE BIOTECHNOLOGIES CLOSES TRANSACTION WITH ANNAPURNA THERAPEUTICS AND FORMS NEW COMPANY, ADVERUM BIOTECHNOLOGIES

2016-05-12 07:10:04 | ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti

2016-05-10 17:08:22 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events

2016-05-10 16:48:03 | Avalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction

2016-05-09 10:16:02 | Avalanche AAVL Reports Wider-than-Expected Q1 Loss

2016-05-06 07:24:04 | Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results

2016-05-06 07:12:49 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen

2016-05-06 07:10:41 | Avalanche Biotech reports 1Q loss

2016-04-27 07:11:31 | Avalanche Biotechnologies to Present at Upcoming Scientific Meetings

2016-04-14 09:22:00 | 5 Stocks Under $10 Set to Soar

2016-04-07 16:14:26 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements

2016-03-15 06:08:08 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events

2016-03-10 16:17:55 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-03-10 13:04:27 | AVALANCHE BIOTECHNOLOGIES, INC. Financials

2016-03-07 16:56:17 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2016-03-04 09:50:02 | Avalanche AAVL Reports Wider-than-Expected Loss in Q4

2016-03-04 06:13:00 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 10-K, Annual Report

2016-03-03 09:36:02 | Avalanche AAVL Posts Wider-than-Expected 4Q Loss

2016-03-03 08:07:38 | Avalanche Biotech reports 4Q loss

2016-03-03 07:24:09 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen

2016-03-02 15:40:08 | What's in Store for Avalanche AAVL This Earnings Season?

2016-02-25 14:33:00 | 4 Biotech Stocks Recommended by Citigroup Analysts

2016-02-22 16:17:35 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-02-19 09:38:00 | Avalanche Shareholders Push Back Against Gene Therapy Reboot Merger

2016-02-17 06:12:29 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2016-02-16 16:12:29 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2016-02-11 08:15:01 | Avalanche Biotechnologies AAVL Jumps: Stock Rises 10.1%

2016-02-02 17:28:10 | Avalanche AAVL Set to Acquire Annapurna Therapeutics

2016-02-02 06:04:01 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements

2016-02-01 14:34:01 | Avalanche Restarts From Bottom

2016-02-01 13:01:55 | Avalance Biotechnologies Tumbles 14% Following Acquisition Announcement

2016-02-01 07:10:15 | Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger

2015-11-20 07:26:15 | Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

2015-08-13 16:48:56 | Avalanche Biotech reports 2Q loss

2015-06-16 17:31:11 | Avalanche Biotech plunges on results from eye drug study

2015-05-13 07:10:00 | Avalanche Biotech reports 1Q loss

2015-03-05 10:10:18 | Avalanche Biotech reports 4Q loss